Cingulate Inc. (CINGW)
NASDAQ: CINGW
· Real-Time Price · USD
0.04
-0.00 (-4.76%)
At close: May 01, 2025, 11:40 AM
0.04
0.00%
After-hours: May 01, 2025, 04:00 PM EDT
-4.76% (1D)
Bid | 0.03 |
Market Cap | 149.77K |
Revenue (ttm) | n/a |
Net Income (ttm) | -3.24B |
EPS (ttm) | -1.732 |
PE Ratio (ttm) | -0.02 |
Forward PE | n/a |
Analyst | n/a |
Ask | 0.04 |
Volume | 2,932 |
Avg. Volume (20D) | 57,664.621 |
Open | 0.03 |
Previous Close | 0.04 |
Day's Range | 0.03 - 0.04 |
52-Week Range | 0.03 - 0.04 |
Beta | -0.88 |
About CINGW
Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of central nervous system and neurobiological disorders. The company's lead product candidates are CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine) for the treatment of attention deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was fo...
Industry Biotechnology
Sector Healthcare
IPO Date n/a
Employees 13
Stock Exchange NASDAQ
Ticker Symbol CINGW
Website https://www.cingulate.com